** Drugmaker's shares up 4.4 pct to life-high afterHikma says Takeda Pharmaceutical unsuccessful inappealing U.S. court decision to deny preliminary injunction ofthe Jordanian company's drug for gout flares.
** Hikma is the top gainer on the FTSE-350 Pharmaceuticals &Biotechnology index
** Co says now preparing to distribute colchicine 0.6 mgcapsules, which were approved by the U.S. Food and DrugAdministration on Sept. 30.
** According to IMS Health, sales of colchicine in the U.S.market were about $688 mln for 12 months ending August 2014,Hikma said in a statement on Sept 30.
** "This should ensure the positive momentum of the pastcouple of years is maintained as growth provided by this $500mln opportunity should compensate any declines to doxycycline inthe company's generics business," Panmure Gordon analyst says (rm://richa.naidu.thomsonreuters.com@reuters.net)
Hikma Pharmaceuticals (HIK)
